A phase III trial, comparing treatment with BRAF inhibitors versus combined treatment with BRAF and MEK inhibitors in patients with BRAF-mutated metastatic melanoma, did indeed find that pain was a major HRQL issue in this population.20 This evidence concerns the gene MAP2K7 and metastatic melanoma.